The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
MDM2 Is a Negative Regulator of p21 , Independent of p53
Open accessAbstract
The MDM2 oncogene has both p53-dependent and p53-independent activities. We have previously reported that antisense MDM2 inhibitors have significant anti-tumor activity in multiple human cancer models with various p53 statuses (Zhang, Z., Li, M., Wang, H., Agrawal, S., and Zhang, R. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 11636-11641). We have also provided evidence that MDM2 has a direct role in the regulation of p21, a cyclin-dependent kinase inhibitor. Here we provide evidence supporting functional interaction between MDM2 and p21 in vitro and in vivo. The inhibition of MDM2 with anti-MDM2 antisense oligonucleotide or Short Interference RNA targeting MDM2 significantly elevated p21 protein levels in PC3 cells (p53 null). In contrast, overexpression of MDM2 diminished the p21 level in the same cells by shortening the p21 half-life, an effect reversed by MDM2 antisense inhibition. MDM2 facilitates p21 degradation independent of ubiquitination and the E3 ligase function of MDM2. Instead, MDM2 promotes p21 degradation by facilitating binding of p21 with the proteasomal C8 subunit. The physical interaction between p21 and MDM2 was demonstrated both in vitro and in vivo with the binding region in amino acids 180-298 of the MDM2 protein. In summary, we provide evidence supporting a physical interaction between MDM2 and p21. We also demonstrate that, by reducing p21 protein stability via proteasome-mediated degradation, MDM2 functions as a negative regulator of p21, an effect independent of both p53 and ubiquitination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044
Transcriptional Regulation of the p21(WAF1/CIP1)Gene
Gartel, A. L., & Tyner, A. L. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4319 · Cited by 664
Kriwacki, R. W., Hengst, L., Tennant, L., Reed, S. I., & Wright, P. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11504 · Cited by 575
Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase
Bornstein, G., Bloom, J., Sitry-Shevah, D., Nakayama, K., Pagano, M., & Hershko, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301774200 · Cited by 494
Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B., & Kouzarides, T. (1995) · Nature · doi:10.1038/375691a0 · Cited by 454
Lin, H.-K. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf406 · Cited by 450
Cited by
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589
“Nonetheless, previous reports showed that p21 ubiquitylation is not a prerequisite for proteasomal degradation and that the p21 ubiquitylation may serve some function other than proteasome degradation via conformation changes (Sheaff et al., 2000; Zhang et al., 2004; Xu et al., 2010).”
BackgroundInfluentialUbiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Structural disorder throws new light on moonlighting
Tompa, P., Szász, C., & Buday, L. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.07.008 · Cited by 473
Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response
Cazzalini, O., Scovassi, A. I., Savio, M., Stivala, L. A., & Prosperi, E. (2010) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2010.01.009 · Cited by 433
Examination of the expanding pathways for the regulation of p21 expression and activity
Jung, Y.-S., Qian, Y., & Chen, X. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.013 · Cited by 423
Self-citationThe MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
Regulating the 20S Proteasome Ubiquitin-Independent Degradation Pathway
Ben-Nissan, G., & Sharon, M. (2014) · Biomolecules · doi:10.3390/biom4030862 · Cited by 336
Hou, J., Wang, D., Zhang, R., & Wang, H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0197 · Cited by 320
Self-citationMDM2 Promotes Proteasome-Dependent Ubiquitin-Independent Degradation of Retinoblastoma Protein
Sdek, P., Ying, H., Chang, D. L. F., Qiu, W., Zheng, H., Touitou, R., Allday, M. J., & Jim Xiao, Z.-X. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.017 · Cited by 288
Nucleolar stress with and without p53
James, A., Wang, Y., Raje, H., Rosby, R., & DiMario, P. (2014) · Nucleus · doi:10.4161/nucl.32235 · Cited by 285
Li, M., Zhang, Z., Hill, D. L., Wang, H., & Zhang, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3066 · Cited by 274
Self-citationChen, D., Zhang, Z., Li, M., Wang, W., Li, Y., Rayburn, E. R., Hill, D. L., Wang, H., & Zhang, R. (2007) · Oncogene · doi:10.1038/sj.onc.1210327 · Cited by 261
Self-citationc-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity
Stepniak, E., Ricci, R., Eferl, R., Sumara, G., Sumara, I., Rath, M., Hui, L., & Wagner, E. F. (2006) · Genes & Development · doi:10.1101/gad.390506 · Cited by 232
“Stability of the p21 protein is largely dependent on the proteasome degradation pathway, which is regulated by interaction with several other proteins such as MDM2, WISp39, and IFI16 (Kwak et al. 2003; Zhang et al. 2004; Jascur et al. 2005).”
BackgroundTargeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182
“HDM2 has also been shown to functionally interact with other proteins including p14ARF, Rb, E2F-1 (Iwakuma and Lozano, 2003) and p21 (Zhang et al., 2004).”
BackgroundHdmx modulates the outcome of p53 activation in human tumor cells
Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163
Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors
Starostina, N. G., & Kipreos, E. T. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.004 · Cited by 147
Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C., & Stockwell, B. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0104 · Cited by 100
The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence
Haferkamp, S., Tran, S. L., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2009) · Aging · doi:10.18632/aging.100051 · Cited by 77
DDB2 (damaged-DNA binding protein 2) in nucleotide excision repair and DNA damage response
Stoyanova, T., Roy, N., Kopanja, D., Raychaudhuri, P., & Bagchi, S. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10109 · Cited by 70
IFN Regulatory Factor 8 Regulates MDM2 in Germinal Center B Cells
Zhou, J. X., Lee, C. H., Qi, C. F., Wang, H., Naghashfar, Z., Abbasi, S., & Morse, H. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803693 · Cited by 47
Self-citationhAda3 regulates p14ARF-induced p53 acetylation and senescence
Sekaric, P., Shamanin, V. A., Luo, J., & Androphy, E. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210462 · Cited by 28
E3 ubiquitin ligases and human papillomavirus-induced carcinogenesis
Lou, Z., & Wang, S. (2014) · Journal of International Medical Research · doi:10.1177/0300060513506655 · Cited by 22
Protecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20
Hdm2- and proteasome-dependent turnover limits p21 accumulation during S phase
Ciznadija, D., Zhu, X.-H., & Koff, A. (2011) · Cell Cycle · doi:10.4161/cc.10.16.16725 · Cited by 11
Metadata
- Authors
- Zhang, Z., Wang, H., Li, M., Agrawal, S., Chen, X., & Zhang, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 279
- Issue
- 16
- Pages
- 16000-16006
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1965531638
- Cited by
- 252
- References
- 28
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.